Chemir has announced the acquisition of Lycoming Analytical Laboratories in central Pennsylvania, a contract laboratory specializing in providing quality control (QC) testing to the pharmaceutical industry. The new company, Chemir Pharma Services, combines the capabilities of the Pennsylvania facility with the services of Chemir’s St. Louis location.
Chemir Pharma Services offers complete CMC solutions for pharmaceutical development. Core services include synthetic chemistry, characterization of drug substance and packaging systems, QC release of API’s and excipients, methods development and validation, preformulation evaluations and stability studies. “We’re excited about this acquisition,” says Phil Meeks, CEO of Chemir Pharma Services. “This acquisition will integrate QC capabilities into Chemir’s core research and development expertise. This combination of services offers our customers a wide range of CMC support activities, enhancing their abilities to bring new medicines to the marketplace.”
Dr. Wayne Way, who will assume the responsibility as President, will head the Pennsylvania facility. Dr. Way has spent the previous six years as President of the St. Louis, MO operations where he was an integral part of the growth and success of Chemir.
